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A recent article from the group in Berlin \[[@B1]\] reports on a retrospective review of observational data comparing their experience using tranexamic acid as an enforced alternative to aprotinin. Their data suggest an increase in morbidity and mortality in the tranexamic acid treated patients. Is this a cause for concern and what does it mean for the future?

The voluntary withdrawal of aprotinin in certain markets has had two major effects. The first was to cause all of the safety and efficacy data for aprotinin to be independently examined by regulatory authorities in both North America and Europe. This process is coming to its conclusion and it is anticipated that, based on a positive benefit-risk ratio, the Canadian authority will renew the marketing license for aprotinin before the end of this year. The European agency is also starting a review \[[@B2]\] but it is not anticipated this process will be completed until 2011.

The second effect of the withdrawal of aprotinin was that clinicians had to find an alternative blood-sparing agent for use during major cardiac surgery. The two alternatives are the lysine analogues epsilon aminocaproic acid and tranexamic acid. Epsilon aminocaproic acid has no approval in Europe or Canada for human administration, leading to the exclusive use of tranexamic acid in these countries.

This shift highlighted a number of problems concerning tranexamic acid. The first was to define an appropriate effective dose. There is only one study investigating a dose-response relationship \[[@B3]\]. This article showed a plateau effect on drains losses with a total dose of 3 grams tranexamic acid but with no observed effect on transfusions. The population studied were patients having low-risk primary myocardial revascularisation. The second problem is that there is no evidence for a benefit of tranexamic acid to reduce transfusion burden in patients at higher risk for transfusions, such as those taking aspirin prior to surgery \[[@B4]\] and those having prolonged bypass periods associated with more complex, typically combined valve and revascularisation surgery. The current article \[[@B1]\] mirrors a meta-analysis showing re-exploration for bleeding is reduced by aprotinin but not tranexamic acid in such patients \[[@B5]\]. Finally, and of crucial importance, there have never been any specifically powered studies to investigate the safety of tranexamic acid.

Over the past months a number of articles have suggested the use of tranexamic acid is not without risk. In an extension of a previous analysis from Toronto, the authors concluded that mortality after cardiac surgery other than primary revascularisation was greater in those patients given tranexamic acid compared to those given high dose aprotinin \[[@B6]\]. An increase in mortality when tranexamic acid was given instead of aprotinin is also a conclusion from the current article \[[@B1]\].

Neurological outcomes is a long standing safety concern as we know administration of tranexamic acid is associated with clinically significant cerebral vasospasm with acute cerebral haemorrhage \[[@B7]\]. The current article \[[@B1]\] shows a three-fold increase in patients having seizures who were allocated to receive high dose tranexamic acid as part of their management during surgery where a cardiac chamber was opened. Can this observation be causally associated with tranexamic acid administration?

The statistical analysis used in the current study was similar to that used to show a deleterious effect of aprotinin, which has subsequently been shown to be flawed. However, an analysis error seems less likely in this case for two reasons. First, a potential mechanism for altering the excitatory neuronal state is recognised. The lysine analogues have marked structural homology with gamma amino butyric acid (GABA) and act as competitive inhibitors in the central nervous system \[[@B8],[@B9]\]. This inhibition is observed clinically as an increase in seizure activity \[[@B9],[@B10]\]. Second, several other groups have independently made the observation of increased seizure activity, mainly in patients having open cardiac chamber procedures \[[@B11],[@B12]\].

What can and should happen next? The European regulatory authority is currently deliberating on not only the licensing for aprotinin but also tranexamic acid \[[@B2]\]. With the increasing body of evidence, it is becoming clearer that aprotinin therapy is of greatest benefit in patients at highest risk (the originally intended patient population \[[@B13]\]). The data also suggest that tranexamic acid in a dose of about 3 to 5 grams may be useful to reduce transfusion burden in patients not taking platelet active medication and having primary myocardial revascularisation. This patient population appears not to have observed safety issues when tranexamic acid was administered \[[@B5]\]. The current study adds to the data questioning if tranexamic acid administration has a place in higher risk cardiac surgery and especially in surgery where a cardiac chamber is opened.
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